Anticipated $-0.07 EPS for BioLineRx Ltd. (BLRX) as of May, 24

May 16, 2018 - By Matthew Medley

BioLineRx Ltd. (NASDAQ:BLRX) Corporate Logo

On May, 24 is anticipated BioLineRx Ltd. (NASDAQ:BLRX)’s earnings report, RTT reports. This year’s EPS analyst estimate is anticipated to be $-0.07. That is 12.50 % up compareed to $-0.08 EPS for last year. 0.00 % EPS growth is what analysts predict. $-0.07 EPS was announced for last quarter. BLRX is touching $0.8863 during the last trading session, after increased 8.09%.BioLineRx Ltd. has 1.34M shares volume, 509.36% up from normal. BLRX is downtrending and has moved 24.35% since May 16, 2017. BLRX underperformed by 35.90% the S&P500.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Coverage

Total analysts of 2 have positions in Biolinerx (NASDAQ:BLRX) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 21, 2017 according to StockzIntelligence Inc Biolinerx has 9 analyst reports. On Thursday, December 21 the firm earned “Buy” rating by Oppenheimer. The stock rating was maintained by Oppenheimer with “Buy” on Tuesday, March 20. On Tuesday, March 6 the firm has “Buy” rating by Oppenheimer given. The stock rating was maintained by H.C. Wainwright with “Buy” on Wednesday, January 17. On Monday, December 4 Oppenheimer maintained BioLineRx Ltd. (NASDAQ:BLRX) rating. Oppenheimer has “Buy” rating and $3.0 target. On Thursday, December 21 the rating was maintained by H.C. Wainwright with “Buy”. On Tuesday, November 21 the firm has “Buy” rating given by H.C. Wainwright. On Tuesday, March 6 H.C. Wainwright maintained the shares of BLRX in report with “Buy” rating. On Monday, December 4 the firm has “Buy” rating by H.C. Wainwright given.

BioLine Rx Ltd, a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs.The firm is worth $93.94 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions.Currently it has negative earnings. The company's other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

More recent BioLineRx Ltd. (NASDAQ:BLRX) news were announced by Benzinga.com, Benzinga.com and Benzinga.com. The first one has “BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid …” as a title and was announced on May 16, 2018. The next is “Benzinga Pro’s 5 Stocks To Watch Today” on May 16, 2018. And last was announced on May 16, 2018, called “40 Stocks Moving In Wednesday’s Mid-Day Session”.

BioLineRx Ltd. (NASDAQ:BLRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: